There is no cure for MS, but there are treatments that can reduce the number and severity of relapses and delay the long-term disability progression of the disease.

There is currently no cure for multiple sclerosis (MS), but there are several treatment options that can help manage it.

The U.S. Food and Drug Administration today approved Tyruko (natalizumab‑sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing forms of multiple sclerosis (MS). Tyruko is approved… for relapsing forms of MS… including clinically isolated syndrome, relapsing‑remitting disease, and active secondary progressive disease. The announcement describes Tyruko as a treatment; it does not state that it cures MS.

The Cleveland Clinic-led Phase 3 HERCULES trial of tolebrutinib in non-relapsing secondary progressive multiple sclerosis (SPMS) "demonstrated a 31% delay in the onset of six-month confirmed disability progression (CDP)" compared with placebo. The release notes that tolebrutinib "suggest[s] that [it] is an effective treatment for non-relapsing SPMS, a form of the disease for which there are currently no U.S. Food and Drug Administration (FDA)-approved treatments." It describes delay in disability progression, not a cure. No language in the announcement claims that multiple sclerosis is cured; it frames tolebrutinib as an investigational treatment improving progression metrics.

A UCSF article on Phase III trials of ocrelizumab (Ocrevus) reports "clinically meaningful" reductions in disability progression in both relapsing MS and primary progressive MS, with up to a 47% reduction in relapses and up to a 43% reduction in disability compared to interferon. Discussing primary progressive MS, it notes that "results that have never been observed in PPMS" were seen in the ORATORIO trial when ocrelizumab was compared with placebo. The article explicitly states: "There currently is no cure for either condition," referring to relapsing multiple sclerosis and primary progressive multiple sclerosis, despite highlighting ocrelizumab as a highly effective new treatment.

Now, the university is paving the way for an MS cure in our lifetimes. In 2013, physician-scientist Ari Green, MD, and neuroscientist Jonah Chan, PhD, made a startling discovery: The over-the-counter antihistamine clemastine repaired damaged myelin in laboratory tests.

A Nature blog discussing Phase III CARE-MS I and II trials of alemtuzumab reports that in these trials 78% and 65% of patients on alemtuzumab remained free of relapse after two years, compared with 47% on interferon beta-1a. The post notes that patients on alemtuzumab showed significantly less brain volume loss and, in one trial, had less disability at the end than at the start, implying some reversal of disability. However, it explicitly states: "There is no cure for the disease," describing multiple sclerosis as a chronic autoimmune condition, and characterizes alemtuzumab as "a robust and effective treatment" rather than a cure.

The Food and Drug Administration on Tuesday approved ocrelizumab (brand name Ocrevus) to treat both relapsing-remitting MS and primary progressive MS, the first time a therapy has been available for severe forms of the disease. There are no cures for MS, and existing treatments only partially reduce symptoms of relapsing-remitting MS.

Monoclonal antibody disease-modifying therapies that target CD20, CD52, and α4 integrin are highly effective at relapse prevention and blocking new brain lesion formation. Near-complete suppression of focal inflammatory disease activity and new MRI lesions is now achievable in the great majority of relapsing patients treated continuously with high-efficacy therapy.

Are there any new treatments to help me fight this disease? There is no cure for multiple sclerosis (MS). However, progress has been made in developing new medicines to treat it. The majority of DMTs approved by the U.S. Food and Drug Administration (FDA) are effective at helping to manage relapsing‑remitting MS.

The review article "Cellular Therapies" in multiple sclerosis summarizes recent phase 3 trials, including tolebrutinib in nonrelapsing secondary progressive MS, which "met its primary endpoint on prevention of [confirmed disability progression] and showed a beneficial effect on confirmed disability improvement." It highlights that this is "the first drug to show a clear treatment effect on CDP and CDI in nrSPMS in a phase 3 trial." The paper also notes failures of other agents (e.g., simvastatin phase 3 trial) and stresses that these are advances in disease modification and progression slowing. Across the discussion, MS is treated as a chronic disease requiring long-term management, and the article does not claim discovery of a cure; instead, it frames current and emerging therapies as high-efficacy disease-modifying or progression-delaying treatments.

"Although dramatic progress has been made against RMS, the development of highly effective therapies against progressive MS remains an unmet need." The article details high-efficacy disease-modifying therapies (including ocrelizumab and autologous hematopoietic stem cell transplantation) that can induce prolonged remission in many patients, but it does not claim that MS can currently be cured and treats it as a chronic disease requiring ongoing management.

Aggressive chemotherapy followed by a stem cell transplant can halt the progression of multiple sclerosis (MS), a small study has suggested. Around 100,000 people in the UK have MS, which is an incurable neurological disease. The authors said that among the survivors, over a period of up to 13 years, there were no relapses and no new detectable disease activity.

Ocrelizumab (Ocrevus). This medicine is approved by the FDA to treat both the relapsing‑remitting and primary‑progressive forms of MS. This treatment reduces the relapse rate and the risk of disabling progression in relapsing‑remitting multiple sclerosis. It also slows the progression of the primary‑progressive form of multiple sclerosis. The page describes disease‑modifying therapies and symptom management; it does not state that any of these are curative.

Queen Mary University of London reports that its researchers' study "shows positive results when treating both primary progressive and relapsing remitting multiple sclerosis with the drug ocrelizumab." It describes this as "first ever positive results" in primary progressive MS, with ocrelizumab reducing signs of disease activity and progression. The article frames ocrelizumab as offering "a new treatment" and emphasizes improved outcomes versus existing options. It does not state that ocrelizumab cures multiple sclerosis; instead it underscores significant treatment benefits in previously untreatable forms of MS.

Researchers at the Dunn School of Pathology at the University of Oxford have played a major role in the development of an effective and innovative treatment for the chronic debilitating disease multiple sclerosis. There is no cure and conventional treatments such as interferon beta require frequent administration and are only moderately effective.

No cure exists for MS, but multiple agents are FDA-approved to manage the condition. Newer therapies, some of them administered orally, have since been discovered with novel mechanisms of action.

An article from UNM Health Sciences Center titled "Clinical Trials Offer Hope for New Multiple Sclerosis" discusses ongoing and recent MS trials, including the VISTA study of PIPE-307 in relapsing-remitting MS. It states that this phase 2 randomized double-blind study is designed to see whether adding PIPE-307 to current treatments improves MS symptoms better than placebo. The piece describes clinical trials as offering hope for "better ways to control or slow MS" and makes clear that current research aims at improving management and outcomes; it does not claim that MS has been cured, and notes that no treatment has yet proven to reliably "turn MS off" for everyone.

"While there isn’t a cure, treatment options can help you manage symptoms and slow disease progression." The page reiterates: "There’s no cure for MS, but treatment is available to help minimize ongoing damage and help you manage symptoms" and describes multiple sclerosis as "a lifelong condition without a cure."

Recent preliminary trial outcomes indicate that multiple sclerosis could be on the verge of a new category of treatment, as two medications show potential in repairing damage linked to the disease. The charity advised that further studies will be necessary before any licensed treatment can be made accessible.

On September 13, 2024, the FDA approved Ocrevus Zunovo (ocrelizumab and hyaluronidase‑ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in adults. Ocrevus Zunovo is a twice‑a‑year, 10‑minute subcutaneous injection… for people with relapsing and progressive multiple sclerosis. The company describes it as a treatment option; it does not claim that it cures MS.

All the CAR-T trials for MS are in extremely early stages. Researchers are exploring whether the approach could work, and Cohen is careful to caution that it may not.

The newest drugs for the treatment of multiple sclerosis include Briumvi, Ponvory, Kesimpta, Bafiertam, Zeposia, Vumerity, Mavenclad, Mayzent, and Ocrevus. Latest FDA Approvals for Multiple Sclerosis… Ocrevus Zunovo (ocrelizumab and hyaluronidase‑ocsq) … Approved September 13, 2024… Indications: RRMS, SPMS, PPMS. The article lists these as treatments and disease‑modifying therapies; it does not describe any as a cure for MS.

Reporting on FDA approval of ocrelizumab, UCSF notes: "There are no cures for MS, and existing treatments only partially reduce symptoms of relapsing-remitting MS. No therapies at all have been effective for primary progressive MS – until now." The story describes ocrelizumab as the first therapy effective for severe forms of MS, offering hope by halting disease activity but not as a cure.

Unfortunately, we now also recognize that the silencing of relapses and MRI activity in RMS is not tantamount to a cure. The jury is out, but there are tantalizing hints that some patients treated with natalizumab, ASCT, and anti-CD20 therapies may achieve elimination of oligoclonal bands.

“Many people with MS can find one that is effective for them. And even though we don’t have a cure or perfect medication yet, scientists are always developing new remedies,” says Dr. Smith. Most are FDA‑approved for relapse‑remitting MS and/or secondary progressive MS; only one, Ocrevus (ocrelizumab), is approved for primary progressive MS. Most recently, in August 2023, the FDA approved the first biosimilar for multiple sclerosis, Tyruko (natalizumab‑sztn)…

A MedLink Neurology review on "Clinical trials in multiple sclerosis" summarizes pivotal trials of disease-modifying therapies such as interferon beta-1b and glatiramer acetate, noting reductions in annualized relapse rates of around 34% compared to placebo. The article emphasizes that these drugs reduce relapse frequency and MRI lesion activity and provide long-term benefits when used continuously, based on follow-up data. It underscores that clinical trials measure endpoints like relapse rate, disability progression, and MRI activity and describes these therapies as disease-modifying, without presenting them as curative; MS is depicted as a chronic condition requiring ongoing treatment.

A PubMed-indexed paper titled "Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit" reviews long-term follow-up of MS therapy trials and concludes that delayed or discontinued treatment provides less benefit than continuous therapy. It reports that a 16-year long-term follow-up study of interferon beta-1b showed an excellent safety profile and lower mortality in treated patients compared with those initially on placebo. The analysis characterizes available treatments as improving long-term outcomes and survival but does not describe any as cures; MS remains a chronic disease where continuous therapy optimizes benefit.

The BBC report on ocrelizumab states: "Both are incurable, although there are treatments for the second state" in reference to relapsing-remitting and primary progressive MS. It calls ocrelizumab "big news" and "a landmark" for slowing brain damage and reducing progression in trial participants, but maintains that multiple sclerosis remains incurable.

"Although there is no cure for MS, we can see a future where people can live free from its effects and not worry about their MS getting worse." The MS Society explains that current drugs can control relapses and progression for many, and that research is focused on stopping MS, repairing myelin, and protecting nerves, but emphasizes that there is presently no cure.

The Food and Drug Administration (FDA) this month (May 2026) approved Ocrevus (ocrelizumab) for the treatment of relapsing‑remitting MS in children and adolescents age 10 and older who weigh 55 pounds or more. The approval makes the intravenously infused medication only the second disease‑modifying therapy (DMT) with an FDA‑sanctioned indication for use in pediatric patients. Both formulations of ocrelizumab are approved for treating relapsing forms of MS and primary‑progressive multiple sclerosis (PPMS).

The FDA has approved a new injectable form of the multiple sclerosis drug ocrelizumab for use in adults with relapsing and progressive forms of the disease. The injection, which is given under the skin, takes only 10 minutes and is given twice a year… The article reports this as an additional treatment option; it does not describe ocrelizumab or its new formulation as a cure.

A feature article "Multiple sclerosis: three trials to watch" notes that "a range of disease-modifying therapies (DMTs) are already approved for MS" and highlights three drugs in Phase III trials: a Bruton’s tyrosine kinase inhibitor, a CD20 cell-depleting antibody, and a DHODH inhibitor. It explains that these agents are being tested against standard therapies or placebo to improve outcomes such as relapse rate and disability progression, including the OVERLORD-MS trial comparing rituximab vs. ocrelizumab. The article portrays the pipeline as focused on enhancing disease modification and progression control; it does not report any trial claiming to cure MS but rather frames these as promising new treatments within a chronic disease framework.

Barry Singer, MD… gives an overview of the anti‑CD20 therapies that are currently FDA‑approved to treat multiple sclerosis (MS) in the USA. Ocrelizumab, administered intravenously twice yearly, is approved for relapsing forms of MS as well as early primary progressive MS. Ofatumumab offers the convenience of subcutaneous self‑administration at home. The latest addition, ublituximab, features a quicker 1‑hour infusion time. These are described as FDA‑approved treatments, not cures.

A patient-oriented clinical trials overview notes that "So far no treatment has reliably 'turned MS off' for everyone, but limited reversal of disability can occur." It explains that many patients regain some function after relapses and that small trials of autologous stem-cell transplantation show 50–70% of carefully selected cases improving disability scores for several years, yet the procedure carries notable risks and is not routine. The page describes current disease-modifying drugs as aiming to "prevent new damage" and mentions that remyelination medicines are under investigation. It states plainly that "a guaranteed, widely available way to reverse MS does not yet exist," indicating that while some approaches can lead to long-term remission or improvement, a general cure has not been discovered.

"Although there is still no cure for MS, the last two decades have seen a revolution in its treatment, offering hope to thousands of MS sufferers in the world." The article from Brown Health discusses disease-modifying therapies, stem cell transplantation and other emerging approaches as moving "towards a cure" but explicitly acknowledges that a cure does not yet exist.

A total of 5 new agents and 1 new dosage formulation were approved by the FDA for the treatment of RRMS since 2010. The US FDA has developed and approved a variety of therapies for the regulation of the immune system, including IFN‑β (Avonex, Betaseron, Extavia, Plegridy, and Rebif), glatiramer acetate (Copaxone), mitoxantrone (Novantrone), natalizumab (Tysabri), fingolimod (Gilenya), Zinbryta (daclizumab), and Ocrevus (ocrelizumab). These are referred to as disease‑modifying therapies rather than curative treatments.

The newest MS treatment to become approved by the FDA is teriflunomide, a compound that blocks rapid white blood cell growth — a key component of the autoimmune processes that cause MS. Teriflunomide is among the first MS drugs that can be administered orally via a daily tablet. Another daily tablet, fingolimod, won FDA approval in 2010. It traps immune cells that contribute to MS inside the lymph glands where they develop and is effective for relapsing forms of MS. The article discusses therapies that modify disease activity, not a cure.

Based on consensus statements from major MS organizations and recent therapeutic reviews, multiple sclerosis is currently regarded as a chronic, immune-mediated neurological disease for which there is no universally accepted cure. Highly effective disease-modifying therapies and, in selected cases, autologous hematopoietic stem cell transplantation can induce long-term remission and markedly reduce relapses and MRI activity, but these outcomes are described as durable disease control or "no evidence of disease activity" (NEDA) rather than cure. Professional guidelines continue to emphasize long-term treatment and monitoring, reflecting that a definitive cure applicable across MS types has not been discovered as of 2025.